In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.

Latest From Kate Rawson

US FDA Communication Ahead Of Major Actions Could Counter Misinformation, Ex-Official Says

Instead of waiting until after regulatory events like COVID boosters and Aduhelm, FDA should describe its decision-making process along the way to help restore public faith in the agency, former deputy commissioner Josh Sharfstein says.

FDA Leadership

OCE 2.0? US FDA Leadership Change May Present Opportunity To Grant Full Review Authority

With a new commissioner expected next year, a restructuring may allow the Oncology Center of Excellence to assume sign-off authority for biologics and devices along with drugs.

Drug Review Leadership

COVID-19 Vaccine ‘Booster’ Or Simply A Third Dose? US FDA’s Marks Starts To Reframe The Issue

It’s a classic example of an internal dispute between an FDA review team and agency leadership playing out at an advisory committee forum, except with the highest possible stakes.

Coronavirus COVID-19 Vaccines

Pazdur To Oncology Drug Developers: Step Back, Slow Down – And Find The Right Dose

FDA’s “Project Optimus” draft guidance on dose optimization is in the works. Until then, randomized dosing studies need to be an IND-level conversation.

Cancer Clinical Trials

US FDA Advisory Committee Reboot (Part III): Asking The Right Questions

Rethinking the voting and discussion questions to advisory committees may be one way to ensure FDA gets the advice it needs.

Advisory Committees Drug Review

US FDA Advisory Committee Reboot (Part II): The Right Balance For Conflicts Of Interest

After back-and-forth tinkering with CoI restrictions, CDER is still finding it challenging to seat the right experts. Maybe more realistic guidelines are needed.

Advisory Committees Drug Review
See All
UsernamePublicRestriction

Register